Physician profile
Michael Christopher Longwell
NPI 1700558046
$2,006.25
in general payments reported to CMS, 2019-2025
13 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $654 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.40 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $499.74 | 2024-2025 | Invega, Spravato |
| Neurocrine Biosciences, INC. | $340.95 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $188.77 | 2024-2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $180.13 | 2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.19 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $150.63 | 2025 | Fanapt |
| Alkermes, INC. | $123.96 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Novo Nordisk INC | $113.85 | 2024-2025 | Wegovy |
| Sage Therapeutics, LLC | $100.00 | 2024 | |
| Lundbeck LLC | $86.96 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $23.50 | 2025 | Zepbound |
| Otsuka America Pharmaceutical, INC. | $14.73 | 2025 | Rexulti |
| Corium, LLC | $7.84 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Longwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.